Orchard Therapeutics Company
Orchard Therapeutics is a biotechnology company that develops and commercializes transformative ex-vivo autologous hematopoietic stem cell gene therapy. Orchard’s portfolio of autologous ex vivo gene therapy programs has demonstrated sustained clinical benefit in over 150 patients across five disease areas. The company is dedicated to transforming the lives of patients with rare diseases through innovative gene therapies.
Investors
Total Funding:
$310.5M
Headquarters:
London, England, United Kingdom
Funding Status:
IPO
Employee Number:
51-100
Estimated Revenue:
$1M to $10M
Investment Stage:
N/A
Last Funding Type:
Series C
Number Of Exists:
Series C
Technology:
Others
Investor Type:
Company
Investors Number:
24
Founded Date:
2015
Industry:
Gene Therapy